Connect with us

Hi, what are you looking for?

Economy

Southeast Asia’s virus hotspot bets on early vaccine rollout

DIMAS ARDIAN/BLOOMBERG

INDONESIA, the world’s fourth most-populous nation that’s battling Southeast Asia’s worst coronavirus outbreak, is gearing for a massive vaccination program that the government wants to start as soon as next month.

The government plans to kick off with an initial 3 million doses in December, prioritizing health workers, police, military and public servants, according to Budi Gunadi Sadikin, who leads the national economic recovery task force. The government expects another 13 million to be inoculated in the first quarter of 2021, with a majority of Indonesians receiving their jabs later in the year.

“I hope the vaccine will come by end of this month, we are trying,” said President Joko Widodo in a Wednesday briefing after supervising a vaccination simulation. “But if it can’t, it will come next month whether in raw material or as a finished good.”

Indonesia is banking on a vaccine as confirmed virus cases surpass 470,000 amid limited testing and contact tracing. The pandemic has driven the economy into its first recession since the Asian financial crisis and unemployment to a nine-year high.

The country needs about 246 million doses to vaccinate 107 million people ages 18 to 59 years old, Health Minister Terawan Agus Putranto said at the Tuesday meeting. The government will shoulder the cost of nearly 74 million doses. The roll-out would pose unique challenges for Indonesia, which would have to distribute vaccines across more than 17,000 islands.

Novavax, Inc. is set to provide 30 million doses of its vaccine candidate, augmenting Indonesia’s supply of 85 million from China’s Sinovac Biotech Ltd. and 57.6 million of the locally produced, Merah Putih Sadikin told parliament on Tuesday. Indonesia doesn’t have any supply deals with Moderna, Inc., Pfizer, Inc. and BioNTech SE which said their vaccines have above 90% efficacy rates.

While a successful COVID-19 vaccine would be a huge step forward for Indonesia, it would not be a “game-changer, at least in the sense that having a vaccine doesn’t stop the pandemic,” according to Panji Fortuna Hadisoemarto, epidemiologist and virologist at Padjadjaran University.

A vaccine will need to be distributed in stages due to limited availability, which means Indonesia will likely only reach sufficiently large coverage after a few months or even more than a year, Mr. Hadisoemarto said. The speed depends on the vaccine supply and distribution as well as the public’s willingness to get inoculated, he added.

Local clinical trials for the Sinovac vaccine are done and subjects have shown no serious adverse effects as of November 6, according to Penny Lukito, head of the country’s food and drug agency.

The first batch of Sinovac vaccines is slated to arrive at the end of this month. The regulator is ready to authorize it for emergency use once it completes data analysis from the clinical trials, or if U.S. and European regulators do the same, Ms. Lukito said.

The emergency use authorization should take about three weeks to process, Mr. Widodo said.

Indonesia also has rights to access as much as 10% of the total supply in the World Health Organization’s (WHO) pooled Covax clinical trials, which includes Moderna and AstraZeneca Plc’s vaccine candidates, according to Mr. Sadikin.

The government will use a digital platform that will allow it to monitor demographic data, logistics, distribution, procurement and implementation of the vaccination program, Mr. Sadikin said. It will also provide the public with a digital dashboard on the progress of inoculation. — Bloomberg

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Get the daily email that makes reading the news actually enjoyable. Stay informed and entertained, for free.
Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

Latest

Economy

THE PHILIPPINES lags regional peers in terms of the share taken up by solar and wind energy in its power mix, energy think tank...

Economy

THE PHILIPPINE government tempered its economic growth target for this year, as rising inflation and ballooning debt threaten to hamper the economy’s recovery from...

Economy

By Keisha B. Ta-asan SOURED LOANS held by Philippine banks declined for a third straight month in May, bringing the nonperforming loan (NPL) ratio...

Economy

THE NATIONAL Government is hoping local government units (LGUs) will channel their expanded budgets into raising agricultural output, Finance Secretary Benjamin E. Diokno said....

Economy

THE MARCOS administration should immediately address power supply shortages and high electricity rates, which are affecting businesses in the country, the Philippine Chamber of...

Economy

MANILA Electric Co. (Meralco) has confirmed receipt of an order from the Energy Regulatory Commission (ERC) directing the country’s largest power distribution utility to...

You May Also Like

Investing

Having a good Instagram marketing agency to back up your Instagram account is an absolute must going into the new year. With competition stronger...

Economy

Ivermectin, an existing drug against parasites including head lice, has had a checkered history when it comes to treating COVID-19. The bulk of studies...

Investing

Insomnia is the most common sleep disorder in the global population. Therefore, it is a problem that many people suffer or have suffered throughout...

Investing

As a traditionally rigid insurance industry becomes bogged down by antiquated processes and operations, a handful of industry leaders are seeking to shake things...

Disclaimer: SmartRetirementReport.com, its managers, its employees, and assigns (collectively "The Company") do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2021 SmartRetirementReport. All Rights Reserved.